COL6A3 (Collagen Type VI Alpha 3 Chain)

Our findings underscore the significant role of rare, high-penetrance genetic variants in FLC susceptibility, particularly in mucin glycosylation and DNA repair genes. These findings offer promising targets for early detection and personalized therapies.

Groups 1 and 3 exhibited linear increases with MA, whereas group 2 showed nonlinear increases. In conclusion, the identification of plasma proteomic biomarkers and their undulating changes in metabolic aging provides a critical foundation for developing clinical markers and precision interventions to prevent accelerated metabolic aging.

This fusion drives tumorigenesis and forms the basis for imatinib treatment, which acts by blocking platelet-derived growth factor receptor-beta kinase activity...In this editorial commentary, we briefly highlight the ever-growing genomic landscape of DFSP, report rare fusions and their biological implications, and examine the role of expanded molecular diagnostics in refining diagnosis, guiding therapy, and informing prognosis. Incorporating comprehensive fusion analysis into routine workup may be critical for accurate classification, especially in unusual presentations where reliance on morphology alone risks misdiagnosis.

Our study defines COL6A3+ GAFs as a key feature of GBM, driving vascular dysfunction and hypoxi, and suggests COL6A3 as a promising therapeutic target for disrupting fibrosis-angiogenesis crosstalk in GBM.

Finally, we speculate on the potential of serum ETP as a prognostic biomarker in both carcinomas and sarcomas. In summary, COL6A3 and ETP are powerful drivers of tumor growth that have potential as noninvasive diagnostic and prognostic tools for the clinical management of cancer.

Our findings highlight the critical role of COL6A3+ TAFs in regulating MDM function and spatial distribution, as well as their contribution to fibrotic tumor vasculature formation. Additionally, we propose targeting COL6A3+ TAFs with cilengitide as a potential therapeutic strategy.

The differentially expressed proteins were mainly associated with metabolic pathways. These analysis provide scientific connotation for the production of high quality dairy products and the healthy development of the dairy industry.

We successfully established a murine cell line LLC-PLM that can serve as a valuable tool for studying pleural metastasis and MPE.

Combined with protein profiling data, we speculate that SNHG11 may be involved in osteosarcoma progression by binding to SERPINB12 and regulating transcription. In conclusion, lncRNA SNHG11 plays a critical role in osteosarcoma development by regulating cellular information carriers at the DNA, RNA, and protein levels.

Tumor microenvironment analysis further reveals enrichments of COL6A3-mediated interactions between immunosuppressive macrophages and tumor cells in recurrent meningiomas. Collectively, these results provide profound insights into the complex evolutionary process of meningiomas and suggest potential therapeutic strategies for the treatment of recurrent tumors.

Recently, the first scRNA-seq dataset in AFX and PDS identified COL6A3 as a novel biomarker. In this review, we synthesize the above datasets and discuss our current understanding of the molecular drivers and prognostic biomarkers in these tumors.

This study provided a novel CBI for patients with advanced ovarian cancer through network analyses and machine learning. CBI could serve as a prognostic prediction tool for patients with advanced ovarian cancer, and also as a potential indicator for immunotherapy.